Aptus Pharma H1 FY27 Revenue at Rs. 489.20 Lacs, PAT Rs. 507.66 Lacs
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 20 Oct 2026, 07:00 PM IST · BSE ID: 68406a87-144e-4e44-a111-c92a05d0695e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its half-year financial report, showing Rs. 489.20 Lacs in revenue and Rs. 507.66 Lacs profit.
🤖 AI Summary
- Aptus Pharma Board approved unaudited financial results for the half year ended September 30, 2026.
- Revenue from operations for H1 FY27 was Rs. 489.20 Lacs, with total income at Rs. 489.68 Lacs.
- Profit After Tax (PAT) for the half year stood at Rs. 507.66 Lacs; Basic EPS was Rs. 2.96.
- The trading window for Designated Persons will open from October 23, 2026.
- Company issued 102.90 lakh bonus shares in May 2026, and a preferential issue of 16,02,870 equity shares is under process.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Half Year Ended Sep 30, 2026)
489.20 Lacs
166.23
Profit Before Tax (Half Year Ended Sep 30, 2026)
562.66 Lacs
136.25
Profit (Loss) For the period (Half Year Ended Sep 30, 2026)
507.66 Lacs
190.62
Basic EPS (Half Year Ended Sep 30, 2026)
2.96
116.06
Share Capital (As at Sep 30, 2026)
1,715.00 Lacs
🏢 How This Affects the Company
The company's press release indicates a nearly 2x year-on-year revenue growth, signifying expansion from a regional to an emerging national pharma company.
Revenue from operations increased to Rs. 489.20 Lacs for H1 FY27 from Rs. 183.75 Lacs in H1 FY26. Profit after tax rose to Rs. 507.66 Lacs from Rs. 174.69 Lacs in the prior comparable period. Equity share capital increased to Rs. 1,715.00 Lacs as of September 30, 2026, from Rs. 686.00 Lacs as of March 31, 2026, due to a bonus issue. Long-term borrowings increased to Rs. 704.27 Lacs from Rs. 52.16 Lacs.
The company's focus on marketing and distribution of finished pharmaceutical formulations remains unchanged as per Segment Reporting notes.
The proposed preferential issue of 16,02,870 equity shares is subject to regulatory and statutory approvals, introducing a dependency risk until completion.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders' equity increased due to the bonus issue of 102.90 lakh shares in May 2026. Future shareholders may be affected by the pending preferential issue.
🔍
Management Signal
The Board's approval of the financial results and efforts towards a preferential issue indicate a focus on growth and capital raising initiatives.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 results — monitor sustained revenue and profit growth
Update on preferential issue — check for regulatory approvals
Changes in long-term borrowings — assess debt management strategies
MEDIUM RISK
Significant increase in long-term borrowings and pending preferential issue expose the company to execution and financing risks.
💡 Investor Takeaway
Aptus Pharma reported a Profit After Tax of Rs. 507.66 Lacs for the half year ended September 30, 2026, a 190.62% increase from Rs. 174.69 Lacs in the prior comparable period. Revenue from operations reached Rs. 489.20 Lacs, marking a 166.23% YoY growth. Basic EPS was Rs. 2.96 for the half year.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from Operations for the half year ended September 30, 2026, increased to Rs. 489.20 Lacs, up 166.23% YoY.
- Profit After Tax for the half year grew to Rs. 507.66 Lacs, a 190.62% increase from Rs. 174.69 Lacs in the prior comparable period.
⚠️ Concerns
- Long-term borrowings significantly increased to Rs. 704.27 Lacs as of September 30, 2026, from Rs. 52.16 Lacs as of March 31, 2026.
- Share Application Money Pending Allotment is zero, despite an approved preferential issue of Rs. 44,88,03,600/- awaiting approvals.
📅 Company Track Record
Aptus Pharma's previous filing on April 28, 2026, for the year ended March 31, 2026, indicated revenue doubling to Rs. 4,670.81 Lakhs but with halving profit growth and margin compression. The current half-year results show renewed profit growth.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aptus Pharma's revenue from operations for the half year ended September 30, 2026?
Aptus Pharma reported revenue from operations of Rs. 489.20 Lacs for the half year ended September 30, 2026.
What was Aptus Pharma's Profit After Tax (PAT) for the half year ended September 30, 2026?
The Profit After Tax for Aptus Pharma for the half year ended September 30, 2026, was Rs. 507.66 Lacs.
What was the Basic Earnings Per Share (EPS) for Aptus Pharma for the half year ended September 30, 2026?
Aptus Pharma's Basic EPS for the half year ended September 30, 2026, was Rs. 2.96.
When did Aptus Pharma issue bonus shares and what was the quantity?
In May 2026, Aptus Pharma issued 102.90 lakh bonus equity shares to its existing shareholders in the ratio of 3:2.
What is the status of Aptus Pharma's proposed preferential issue?
Aptus Pharma's preferential issue of 16,02,870 equity shares, aggregating to Rs. 44,88,03,600/-, has been approved by members but is currently awaiting requisite regulatory and statutory approvals.
Questions based on this BSE filing only. For information purposes.